|
1
|
Forastiere AA, Leong T, Rowinsky E, et al:
Phase III comparison of high-dose paclitaxel + cisplatin +
granulocyte colony-stimulating factor versus low-dose paclitaxel +
cisplatin in advanced head and neck cancer: Eastern Cooperative
Oncology Group Study E1393. J Clin Oncol. 19:1088–1095. 2001.
|
|
2
|
Samlowski WE, Gundacker H, Kuebler JP, et
al: Evaluation of gemcitabine in patients with recurrent or
metastatic squamous cell carcinoma of the head and neck: a
Southwest Oncology Group phase II study. Invest New Drugs.
19:311–315. 2001. View Article : Google Scholar
|
|
3
|
Samlowski WE, Lew D, Kuebler PJ, et al:
Evaluation of Tomudex in patients with recurrent or metastatic
squamous cell carcinoma of the head and neck: a Southwest Oncology
Group study. Invest New Drugs. 16:271–274. 1998. View Article : Google Scholar
|
|
4
|
Smith RE, Lew D, Rodriguez GI, Taylor SA,
Schuller D and Ensley JF: Evaluation of topotecan in patients with
recurrent or metastatic squamous cell carcinoma of the head and
neck. A phase II Southwest Oncology Group study. Invest New Drugs.
14:403–407. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Specenier PM and Vermorken JB: Current
concepts for the management of head and neck cancer: chemotherapy.
Oral Oncol. 45:409–415. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vermorken JB, Mesia R, Rivera F, et al:
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Forastiere AA, Metch B, Schuller DE, et
al: Randomized comparison of cisplatin plus fluorouracil and
carboplatin plus fluorouracil versus methotrexate in advanced
squamous-cell carcinoma of the head and neck: a Southwest Oncology
Group study. J Clin Oncol. 10:1245–1251. 1992.PubMed/NCBI
|
|
8
|
Gibson MK, Li Y, Murphy B, et al:
Randomized phase III evaluation of cisplatin plus fluorouracil
versus cisplatin plus paclitaxel in advanced head and neck cancer
(E1395): an intergroup trial of the Eastern Cooperative Oncology
Group. J Clin Oncol. 23:3562–3567. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim S, Yazici YD, Calzada G, et al:
Sorafenib inhibits the angiogenesis and growth of orthotopic
anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer
Ther. 6:1785–1792. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Elser C, Siu LL, Winquist E, et al: Phase
II trial of sorafenib in patients with recurrent or metastatic
squamous cell carcinoma of the head and neck or nasopharyngeal
carcinoma. J Clin Oncol. 25:3766–3773. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Williamson SK, Moon J, Huang CH, et al:
Phase II evaluation of sorafenib in advanced and metastatic
squamous cell carcinoma of the head and neck: Southwest Oncology
Group Study S0420. J Clin Oncol. 28:3330–3335. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Escudier B, Eisen T, Stadler WM, et al:
Sorafenib for treatment of renal cell carcinoma: final efficacy and
safety results of the phase III treatment approaches in renal
cancer global evaluation trial. J Clin Oncol. 27:3312–3318. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Banerjee SK, Weston AP, Zoubine MN,
Campbell DR and Cherian R: Expression of cdc2 and cyclin B1 in
Helicobacter pylori-associated gastric MALT and MALT
lymphoma: relationship to cell death, proliferation, and
transformation. Am J Pathol. 156:217–225. 2000.PubMed/NCBI
|
|
14
|
Stephenson JM, Banerjee S, Saxena NK,
Cherian R and Banerjee SK: Neuropilin-1 is differentially expressed
in myoepithelial cells and vascular smooth muscle cells in
preneoplastic and neoplastic human breast: a possible marker for
the progression of breast cancer. Int J Cancer. 101:409–414. 2002.
View Article : Google Scholar
|
|
15
|
Olsson AK, Dimberg A, Kreuger J and
Claesson-Welsh L: VEGF receptor signalling - in control of vascular
function. Nat Rev Mol Cell Biol. 7:359–371. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shibuya M and Claesson-Welsh L: Signal
transduction by VEGF receptors in regulation of angiogenesis and
lymphangiogenesis. Exp Cell Res. 312:549–560. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gold KA, Lee HY and Kim ES: Targeted
therapies in squamous cell carcinoma of the head and neck. Cancer.
115:922–935. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mac Gabhann F and Popel AS: Differential
binding of VEGF isoforms to VEGF receptor 2 in the presence of
neuropilin-1: a computational model. Am J Physiol Heart Circ
Physiol. 288:H2851–H2860. 2005.PubMed/NCBI
|
|
19
|
Soker S, Miao HQ, Nomi M, Takashima S and
Klagsbrun M: VEGF165 mediates formation of complexes containing
VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J
Cell Biochem. 85:357–368. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Folkman J: Antiangiogenesis in cancer
therapy - endostatin and its mechanisms of action. Exp Cell Res.
312:594–607. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rizzolio S and Tamagnone L: Multifaceted
role of neuropilins in cancer. Curr Med Chem. 18:3563–3575. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Saharinen P, Eklund L, Pulkki K, Bono P
and Alitalo K: VEGF and angiopoietin signaling in tumor
angiogenesis and metastasis. Trends Mol Med. 17:347–362. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Neuchrist C, Erovic BM, Handisurya A, et
al: Vascular endothelial growth factor C and vascular endothelial
growth factor receptor 3 expression in squamous cell carcinomas of
the head and neck. Head Neck. 25:464–474. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Scott PA, Smith K, Poulsom R, De Benedetti
A, Bicknell R and Harris AL: Differential expression of vascular
endothelial growth factor mRNA vs protein isoform expression in
human breast cancer and relationship to eIF-4E. Br J Cancer.
77:2120–2128. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Usui T, Ishida S, Yamashiro K, et al:
VEGF164(165) as the pathological isoform: differential leukocyte
and endothelial responses through VEGFR1 and VEGFR2. Invest
Ophthalmol Vis Sci. 45:368–374. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Karjalainen K, Jaalouk DE, Bueso-Ramos CE,
et al: Targeting neuropilin-1 in human leukemia and lymphoma.
Blood. 117:920–927. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kreuter M, Woelke K, Bieker R, et al:
Correlation of neuropilin-1 overexpression to survival in acute
myeloid leukemia. Leukemia. 20:1950–1954. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lu L, Zhang L, Xiao ZJ, et al: Expression
and effect of neuropilin-1 in acute myeloid leukemic cells.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 15:1150–1155. 2007.(In
Chinese).
|
|
30
|
Vanveldhuizen PJ, Zulfiqar M, Banerjee S,
et al: Differential expression of neuropilin-1 in malignant and
benign prostatic stromal tissue. Oncol Rep. 10:1067–1071.
2003.PubMed/NCBI
|
|
31
|
Hong TM, Chen YL, Wu YY, et al: Targeting
neuropilin 1 as an antitumor strategy in lung cancer. Clin Cancer
Res. 13:4759–4768. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mac Gabhann F and Popel AS: Targeting
neuropilin-1 to inhibit VEGF signaling in cancer: comparison of
therapeutic approaches. PLoS Comput Biol. 2:e1802006.PubMed/NCBI
|
|
33
|
Mac Gabhann F and Popel AS: Interactions
of VEGF isoforms with VEGFR-1, VEGFR-2, and neuropilin in vivo: a
computational model of human skeletal muscle. Am J Physiol Heart
Circ Physiol. 292:H459–H474. 2007.PubMed/NCBI
|
|
34
|
Zhang S and Kong W: Expression of
neuropilin-1 in human laryngeal carcinoma and cell lines. Lin
Chuang Er Bi Yan Hou Ke Za Zhi. 20:634–635. 2006.(In Chinese).
|
|
35
|
Bonner JA, Harari PM, Giralt J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bonner JA, Harari PM, Giralt J, et al:
Radiotherapy plus cetuximab for locoregionally advanced head and
neck cancer: 5-year survival data from a phase 3 randomised trial,
and relation between cetuximab-induced rash and survival. Lancet
Oncol. 11:21–28. 2010.PubMed/NCBI
|
|
37
|
Frampton JE: Cetuximab: a review of its
use in squamous cell carcinoma of the head and neck. Drugs.
70:1987–2010. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cavalot A, Martone T, Roggero N, Brondino
G, Pagano M and Cortesina G: Prognostic impact of HER-2/neu
expression on squamous head and neck carcinomas. Head Neck.
29:655–664. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shiga H, Rasmussen AA, Johnston PG, et al:
Prognostic value of c-erbB2 and other markers in patients treated
with chemotherapy for recurrent head and neck cancer. Head Neck.
22:599–608. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xia W, Lau YK, Zhang HZ, et al:
Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor
for the outcome of oral squamous cell carcinoma than any individual
family members. Clin Cancer Res. 5:4164–4174. 1999.PubMed/NCBI
|
